AccurKardia vs HeartSciences (2026)
If your failure mode is buying the HeartSciences name expecting HeartSciences' AI, read the regulatory line first. What a facility can purchase from HeartSciences in 2026 is an ECG reporting and management platform plus marketplace access to a third party's cleared model, from Bunkerhill Health, separately indexed here. Its own AI-ECG algorithms, for impaired cardiac relaxation and low ejection fraction, are not cleared and not commercially available. AccurKardia is the opposite: the algorithm is the entire product. Its AccurECG system holds two FDA 510(k) clearances, most recently a version 2.0 covering thirteen rhythm classifications in adults, and runs device agnostically across patches, Holter monitors, and telemetry. The honest split is availability. AccurKardia ships cleared interpretation today; HeartSciences ships the workflow and the distribution while its own models wait on the FDA.
- The algorithm is cleared and shipping today: two FDA 510(k) clearances, most recently version 2.0 under K252361 covering thirteen rhythm classifications in adults, which is regulator reviewed performance rather than a vendor claim.
- Device agnostic by design: it ingests ECG data from patches, Holter monitors, event recorders, and telemetry without custom integration, so a monitoring company or OEM can adopt without re platforming.
- An explicit no black box position with explainable output, which is the mechanism that makes the required physician over read meaningful rather than a rubber stamp.
- If you want a route to cleared AI-ECG for a smaller facility, the marketplace is the argument: it is positioned to bring cleared algorithms to community hospitals, critical access hospitals, and primary care, where cardiology reading is least available, starting with Bunkerhill's cleared ejection fraction model.
- It names the reimbursement pathway explicitly, assistive AI-ECG under the Hospital Outpatient Prospective Payment System at APC 5734, which lets a buyer model the revenue offset directly, something very few vendors here enable.
- It reports its own regulatory status candidly, separating device and algorithm submissions and explaining why, so a buyer is not misled about what is and is not cleared.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. AccurKardia and HeartSciences are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | AccurKardia | HeartSciences |
|---|---|---|
| Primary category | Diagnostics & Genomics | Diagnostics & Genomics |
| Founded | 2019 | Not recorded |
| Headquarters | New York, New York, United States | Southlake, Texas |
| Website | accurkardia.com | heartsciences.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards AccurKardia its top capability grade on AI Centrality and FDA and Regulatory Status. Set against HeartSciences, AccurKardia grades higher on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards HeartSciences its top capability grade on Setting and Specialty Coverage. Set against AccurKardia, HeartSciences grades higher on Commercial Transparency and Setting and Specialty Coverage. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose AccurKardia or HeartSciences?
On the axes where the AI Health Index separates them, AccurKardia grades higher on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence, and HeartSciences grades higher on Commercial Transparency and Setting and Specialty Coverage. AccurKardia leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do AccurKardia and HeartSciences differ most?
The widest separation the AI Health Index records between AccurKardia and HeartSciences is on AI Centrality, where AccurKardia grades A and HeartSciences grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do AccurKardia and HeartSciences grade the same?
The AI Health Index grades AccurKardia and HeartSciences the same on several axes, including Autonomy and Oversight Model, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have AccurKardia and HeartSciences not disclosed?
At the last review, at least one of AccurKardia and HeartSciences published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
The decisive fact is what each sells today. HeartSciences is graded C on AI centrality and FDA status because its own algorithms are not cleared or available; the cleared model in its marketplace belongs to Bunkerhill, and buying MyoVista Insights in 2026 means buying ECG workflow software plus access to someone else's model.
AccurKardia carries the clearances but publishes no SOC 2, HIPAA, or PHI framework, which FDA clearance does not substitute for, and its 99 percent accuracy figure is vendor stated without peer reviewed prospective or head to head comparison against cardiologist over read. Its Breakthrough Device Designation for a hyperkalemia tool is an expedited review status, not a clearance.